Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li><strong>Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. </strong></li>
<li>Hong Kong ECM took yet another hit with China Tourism Group deciding to delay its H-Share listing citing poor market condition</li>
<li>On 2nd Dec 2021, SEC issued the final amendments for implementation of HFCAA which will China ADRs going forward. </li>
</ul>


Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. 
Hong Kong ECM took yet another hit with China Tourism Group deciding to delay its H-Share listing citing poor market condition
On 2nd Dec 2021, SEC issued the final amendments for implementation of HFCAA which will China ADRs going forward. 


ECM Weekly (5th December 2021) - Weibo, Asymchem, Grab, Yonghe, Gushengtang, Siam Makro, SF Intra

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Yonghe Medical Group / Equity Capital Markets

<ul>
<li>Yonghe Medical, the leading hair transplant clinic chain in China launched book building to raise up to USD 191m via a Hong Kong listing.</li>
<li>In the previous note, we look at the company's service, key operating metrics, and the financials. We also provided our thoughts on valuation.</li>
<li>In this note, we provide an update for the book building. We will run the deal through our ECM framework and provide an update on the deal.</li>
</ul>


Yonghe Medical, the leading hair transplant clinic chain in China launched book building to raise up to USD 191m via a Hong Kong listing.
In the previous note, we look at the company's service, key operating metrics, and the financials. We also provided our thoughts on valuation.
In this note, we provide an update for the book building. We will run the deal through our ECM framework and provide an update on the deal.


Yonghe Medical (雍禾医疗) IPO: Fairly Valued

<ul>
<li>Yonghe Medical is a leading hair transplant clinic chain in China. The company is looking to raise up to USD 300 million via a Hong Kong listing.</li>
<li>We look at the company's service, key operating metrics, and the financials. We also provide our thoughts on valuation.</li>
<li>We think the company has an interesting angle but we also highlight the key issue of its business model.</li>
</ul>


Yonghe Medical is a leading hair transplant clinic chain in China. The company is looking to raise up to USD 300 million via a Hong Kong listing.
We look at the company's service, key operating metrics, and the financials. We also provide our thoughts on valuation.
We think the company has an interesting angle but we also highlight the key issue of its business model.


Yonghe Medical (雍禾医疗) Pre-IPO: Sales-Driven Business Model

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<p>Modern fast pace of life and huge work pressure make hair loss anxiety spread to all kinds of groups. As people pay more attention to hair, the awareness of hair health and management is gradually awakening, and hair transplantation is one of the solutions. On June 17, <a href="https://www.smartkarma.com/entities/yonghe-medical-group-co-ltd" target="_blank" data-smartkarma-citation="entities:33521:1" rel="noopener">Yonghe Medical Group (YMG HK)</a> formally submitted its prospectus to the HKEX and planned to be listed on the main board. If everything goes well, Yonghe will be the first listed company in the field of hair transplantation in China. However, despite the promising market potential, there are some concerns of the Company that deserve investors’ attention.</p>

Modern fast pace of life and huge work pressure make hair loss anxiety spread to all kinds of groups. As people pay more attention to hair, the awareness of hair health and management is gradually awakening, and hair transplantation is one of the solutions. On June 17, Yonghe Medical Group (YMG HK) formally submitted its prospectus to the HKEX and planned to be listed on the main board. If everything goes well, Yonghe will be the first listed company in the field of hair transplantation in China. However, despite the promising market potential, there are some concerns of the Company that deserve investors’ attention.

Pre-IPO Yonghe Medical Group - Here Are the Concerns

China

Yonghe Medical Group provides comprehensive hair-related healthcare services, including hair transplant, medical hair care, and routine hair restoration. The company also offers medical wig products and other ancillary services. It is headquartered in Beijing, China, and was founded in 2005.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yonghe Medical Group (2279 HK)

ECM Weekly (5th December 2021) - Weibo, Asymchem, Grab, Yonghe, Gushengtang, Siam Makro, SF Intra

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Yonghe Medical (雍禾医疗) IPO: Fairly Valued

We provide an update for Yonghe Medical's book building. We think the deal is fairly valued against our valuation and will not participate in the...

Ke Yan, CFA, FRM

Yonghe Medical (雍禾医疗) Pre-IPO: Sales-Driven Business Model

Yonghe Medical is a leading hair transplant clinic chain in China. We look at the company's service, key operating metrics, and the financials. We...

Ke Yan, CFA, FRM

Pre-IPO Yonghe Medical Group - Here Are the Concerns

The article analyzed Yonghe Medical Group in terms of the concerns and challenges that deserve investors’ attention,including the business...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)